Sex difference in brain CB1 receptor availability in man by Laurikainen, Heikki et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.neuroimage.2018.10.013
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Laurikainen, H., Tuominen, L., Tikka, M., Merisaari, H., Armio, R-L., Sormunen, E., ... Hietala, J. (2018). Sex
difference in brain CB1 receptor availability in man. NeuroImage.
https://doi.org/10.1016/j.neuroimage.2018.10.013
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 10. Jul. 2020
Accepted Manuscript
Sex difference in brain CB1 receptor availability in man
Heikki Laurikainen, Lauri Tuominen, Maria Tikka, Harri Merisaari, Reetta-Liina Armio,
Elina Sormunen, Faith Borgan, Mattia Veronese, Oliver Howes, Merja Haaparanta-
Solin, Olof Solin, Jarmo Hietala
PII: S1053-8119(18)31972-4
DOI: 10.1016/j.neuroimage.2018.10.013
Reference: YNIMG 15332
To appear in: NeuroImage
Received Date: 28 February 2018
Revised Date: 20 September 2018
Accepted Date: 4 October 2018
Please cite this article as: Laurikainen, H., Tuominen, L., Tikka, M., Merisaari, H., Armio, R.-L.,
Sormunen, E., Borgan, F., Veronese, M., Howes, O., Haaparanta-Solin, M., Solin, O., Hietala, J.,
METSY group, Sex difference in brain CB1 receptor availability in man, NeuroImage (2018), doi: https://
doi.org/10.1016/j.neuroimage.2018.10.013.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 1
Sex difference in brain CB1 receptor availability in man 1 
Heikki Laurikainen1,2,, Lauri Tuominen1,2,5, Maria Tikka2, Harri Merisaari1, Reetta-2 
Liina Armio1,2, Elina Sormunen1,2, Faith Borgan3, Mattia Veronese4, Oliver Howes3, 3 
Merja Haaparanta-Solin1, Olof Solin1, Jarmo Hietala1,2* and METSY group 4 
  5 
1 Turku PET Centre, Turku University Hospital, Finland.  6 
2 Department of Psychiatry, University of Turku and Turku University Hospital, Finland. 7 
3 Psychosis Studies Department, Institute of Psychiatry, Psychology & Neuroscience, King's College 8 
London, UK. 9 
4 Department of Neuroimaging, Institute of Psychiatry, Psychology & Neuroscience, King's College 10 
London, UK. 11 
5 Martinos Center for Biomedical Imaging, Harvard Medical School, Boston, MA, USA. 12 
 13 
* Corresponding author: Department of Psychiatry, University of Turku, Kunnallissairaalantie 20, 14 
Building 9, 20700 Turku, Finland, email: jahi@utu.fi 15 
 16 
Abstract 17 
 18 
The endocannabinoid system (ECS) has a widespread neuromodulatory function in 19 
the central nervous system and is involved in important aspects of brain function 20 
including brain development, cortical rhythms, plasticity, reward, and stress 21 
sensitivity. Many of these effects are mediated via the cannabinoid CB1 receptor 22 
(CB1R) subtype. Animal studies convincingly show an interaction between the ECS  23 
and sex hormones, as well as a sex difference of higher brain CB1R in males. Human 24 
in vivo studies of sex difference have yielded discrepant findings.  25 
 26 
Gender differences in CB1R availability were investigated in vivo in 11 male and 11 27 
female healthy volunteers using a specific CB1R tracer [18F]FMPEP-d2 and positron 28 
emission tomography (PET). Regional [18F]FMPEP-d2 distribution volume was used 29 
as a proxy for CB1R availability. In addition, we explored whether CB1R availability 30 
is linked to neuropsychological functioning. 31 
 32 
Relative to females, CB1R availability was on average 41% higher in males 33 
(p=0.002) with a regionally specific effect larger in the posterior cingulate and 34 
retrosplenial cortices (p=0.001). Inter-subject variability in CB1R availability was 35 
similar in both groups. Voxel-based analyses revealed an inverse association between 36 
CB1R availability and visuospatial working memory task performance in both groups 37 
(p<0.001). 38 
 39 
A CB1R sex difference with a large effect size was observed and should be 40 
considered in the design of CB1R-related studies on neuropsychiatric disorders. The 41 
behavioural correlates and clinical significance of this difference remain to be further 42 
elucidated, but our studies suggest an association between CB1R availability and 43 
working memory.   44 
 45 
Key words: endocannabinoid, cb1 receptor, sex difference, working memory 46 
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1 INTRODUCTION 47 
 48 
The endocannabinoid system (ECS) is a ubiquitous modulatory and homeostatic 49 
system in the human body1. In the central nervous system, the ECS is involved in 50 
multiple neurodevelopmental processes2, cognitive functions3, and the regulation of 51 
emotion and responses to stress4. The ECS consists of lipid derived endocannabinoid 52 
ligands, the enzymes constituting their metabolic routes, and two G-protein coupled 53 
receptors - endocannabinoid receptor type 1 and 2 (CB1R and CB2R respectively). 54 
The main endocannabinoids, anandamide (AEA) and 2-arachidonoylglycerol (2-AG) 55 
are synthesised on the postsynaptic membrane in response to depolarization. They 56 
modulate neural activity by acting retrogradely on presynaptic CB1R to transiently 57 
suppress further neurotransmitter release. Additionally, the ECS can affect synaptic 58 
plasticity through long-term depression of function (LTD)5. The main functional site 59 
of ECS modulation has been proposed to be at glutamatergic and GABAergic 60 
synapses resulting in balancing excitation and inhibition of cortical pyramidal cells, 61 
and local circuit modulation of midbrain projections.5–7 It is currently unclear whether 62 
these roles of ECS in plasticity and neurodevelopment have an impact on known sex 63 
differences in histology and morphology of the human cortex8,9. 64 
 65 
Converging lines of evidence from pre-clinical studies show gender differences in 66 
ECS function. Relative to female rodents, male rodents show greater levels of CB1R 67 
protein10, mRNA11, receptor density12,13 and agonist binding14. However, in vivo 68 
studies investigating CB1R availability in humans have yielded discrepant findings, 69 
reporting decreased and increased CB1R availability in males relative to females 15–17. 70 
These widespread or global differences were measured in comparable samples of 71 
healthy control subjects without recent cannabis exposure, but unfortunately 72 
comparison is hampered by differences in quantification and properties of CB1R PET 73 
radioligands18. 74 
 75 
Development of the ECS can be described as transactional. Pre-clinical studies 76 
showing ECS sex differences in response developmental stress exposure suggest that 77 
environmental factors may contribute to different adult ECS phenotypes in males and 78 
females10,13,19. Additionally, chronic exposure to a CB1R agonist during early 79 
development results in long term sex dependent changes in cognitive performance in 80 
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rats12. This is in line with human data suggesting greater impact of chronic cannabis 81 
exposure to visuospatial memory performance in females20. Human studies generally 82 
associate the ECS with cognition21. In a recent double blind placebo controlled 83 
crossover study a low dose of sublingual ∆9-THC resulted in reduction of spatial span 84 
task errors in males, and an increase in females22. This sex dependent effect of the 85 
ECS on visuospatial performance is notable as this domain seems to have sex 86 
differences in humans23. Animal studies consistently support the association of 87 
visuospatial memory and the ECS24–29; e.g. spatial working memory is selectively 88 
impaired in male rhesus monkeys after i.v. ∆9-THC injection30. 89 
 90 
CB1R availability in the human brain is proportional to tracer binding measured as 91 
tracer distribution volume (VT) using compartmental modelling31. VT is defined as the 92 
relationship of tissue concentration of bound radioligand (CT) to plasma concentration 93 
of unchanged radioligand (CP) at kinetic equilibrium32. We used [18F]FMPEP-d2, a 94 
novel inverse agonist CB1R PET radioligand, to measure CB1R availability in 95 
healthy male and female volunteers. The retest variability of [18F]FMPEP-d2 plasma 96 
measurements are good (16%), uptake into the human brain is high, and binding is 97 
highly specific (80-90%). Similarly, the test-retest variability (14%), intersubject 98 
variability (26%), and intra-class correlation (ICC=0.89) of [18F]FMPEP-d2 VT are 99 
good33,34. Despite being highly lipophilic the combination of [18F]FMPEP-d2 test-100 
retest stabilities of VT/plasma measurements and binding specificity seem to be 101 
superior to other currently available CB1R PET radioligands16,33,35–37. 102 
 103 
Previous studies have successfully used [18F]FMPEP-d2 VT to demonstrate group 104 
effects of chronic cannabis use and alcohol dependence on CB1R availability38,39. In 105 
addition to substance-related disorders, the ECS has also been suggested to be 106 
involved in the etiology of other psychiatric disorders, such as mood and anxiety 107 
disorders15,40, and schizophrenia41,42. The clinical use of CB1R antagonist rimonabant 108 
increased the risk for significant depressive symptoms in patients with 109 
obesity/metabolic disorders43 leading to withdrawal from market. Considering the 110 
consistent gender differences in incidence of these psychiatric disorders, and the 111 
widespread role of ECS in brain function, characterizing a ECS sex difference could 112 
lead to novel insight into the vulnerability mechanisms of neuropsychiatric disorders. 113 
We hypothetized that males would show greater CB1R availability relative to females 114 
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using [18F]FMPEP-d2 and 3D-PET. We also explored whether CB1R is associated 115 
with neuropsychological function. 116 
 117 
2 MATERIALS AND METHODS 118 
 119 
The study protocol was approved by the Joint Ethical Committee of the University of 120 
Turku and the Turku University Central Hospital. The study was conducted according 121 
to the Declaration of Helsinki. Informed consent was obtained from all human 122 
subjects prior to their participating in the study. 123 
 124 
2.1 Subjects 125 
 126 
We recruited 28 healthy individuals from the national population registry, local 127 
educational institutions, and by local newspaper advertisement. The somatic status of 128 
all the subjects was confirmed by medical examination, blood and urine tests, 129 
electrocardiography, and a structured clinical interview for DSM-IV axis I disorders 130 
(SCID-I/NP). Pregnancy was ruled out by urine and/or blood screening. Subjects with 131 
a chronic medical or neurological condition affecting the brain, history of head trauma 132 
with loss of consciousness, and neurodevelopmental disorders were excluded. 133 
Lifetime substance use was documented, and current use was controlled with a urine 134 
screen prior to the PET scan. Subjects with a lifetime DSM-IV Axis I diagnosis, 135 
substance-related disorder, or who had used any illicit substances two months prior to 136 
scanning, were excluded. All subjects underwent a structural MRI scan with the 137 
Philips 3T Ingenuity PET/MR hybrid scanner to exclude any structural abnormalities. 138 
Four subjects were ruled out from statistical tests due to technical failure resulting in 139 
incomplete blood data (n=3) or incomplete PET data (n=1). Two subjects with frame-140 
by-frame motion exceeding 4 mm, and significant or continuous motion in tracking 141 
data, were excluded. Overall, the study sample regarding statistical tests of 142 
[18F]FMPEP-d2 VT consisted of 22 of the 28 scanned subjects. 143 
To approximate serum estradiol concentration during PET, the phase of ovarian cycle 144 
of females was determined as either early follicular (<9 d), late luteal (>24 d), or late 145 
follicular to mid-luteal phase (9-23 d) according to days from start of last 146 
menstruation44. Use of hormonal contraception or menopause were documented as 147 
these affect serum estradiol levels45. Six females had combined oral contraceptives 148 
containing estrogen and progestin, four had no contraception and one subject had a 149 
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recent menopause. According to ovarian cycle no subjects without contraception was 150 
in the ‘late follicular to mid-luteal’ phase. The cycle phase for one female subject 151 
could not be classified due to missing data. 152 
 153 
2.2 Radiochemistry 154 
 155 
[18F]FMPEP-d2 was synthesized as described previously46 with slight modifications. 156 
The radiochemical purity was greater than 95% and the molar radioactivity greater 157 
than 500 GBq/µmol at the end of synthesis. 158 
 159 
2.3 Positron emission tomography 160 
 161 
An individually molded thermoplastic mask was used to restrain head movement 162 
during the scan. The tracer [18F]FMPEP-d2 was given as an antecubital intravenous 163 
bolus injection. Emission data was gathered in 3D list-mode first for 60 minutes with 164 
the brain-dedicated high-resolution research tomograph (ECAT HRRT, Siemens 165 
Medical Solutions). Subjects then came out of the scanner for 30 minutes, after which 166 
the scan was continued for another 30 minutes for a total scan range of 0 to 120 167 
minutes. 168 
Emission data were reconstructed using a 3D-OSEM algorithm into 19 frames of 169 
increasing length (3x1 min, 5x3 min, 7x6 min and 4x7.5 min) with a 1.22x1.22x1.22 170 
mm
3
 isometric voxel-size. Head motion during the scan was corrected by realigning 171 
all PET frames to the 12th frame containing the highest uptake on average. Individual 172 
frame-to-frame motion correction parameters were inspected and subjects with 173 
motion exceeding a predefined 4mm in any direction were scrutinized using head 174 
motion tracking data collected during the scan (Polaris, Northern Digital Inc., 175 
Canada). Cortical reconstruction and volumetric segmentation of the T1 weighted MR 176 
image were performed with Freesurfer version 5.3.0 177 
(http://surfer.nmr.mgh.harvard.edu/). The T1 weighted image, now in the same space 178 
as the freesurfer atlas, was coregistered to the sum of the realigned PET frames using 179 
SPM12 and Matlab R2014b (The Mathworks Inc., Sherborn, Massachusetts) and the 180 
same transformations were also applied to the Desikan-Killiany atlas in alignment 181 
with the T1 weighted image. This atlas was then used to extract masks to define 182 
volumes of interest (VOI) on the PET time series. To facilitate cross study 183 
comparison of [18F]FMPEP-d2 VT, VOI selection was a rough adaptation from a 184 
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previous [18F]FMPEP-d2 human study38, and mimicked the exhaustive or composite 185 
VOIs used in previous human studies of CB1R sex difference15–17. Mean time activity 186 
curves were derived from all 17 VOIs (amygdala, anterior cingulate cortex, 187 
brainstem, caudate nucleus, cerebellum, frontal cortex, hippocampus, insula, occipital 188 
cortex, orbitofrontal cortex, parahippocampal gyrus, parietal cortex, posterior 189 
cingulate cortex, prefrontal cortex, putamen, temporal cortex and thalamus).  190 
 191 
2.4 Arterial plasma sampling and analyses for input function 192 
 193 
Following tracer injection, whole blood activity was measured using continuous 194 
sampling for the first 3.5 minutes using Allogg ABSS (Allogg AB, Mariefred, 195 
Sweden, http://www.allogg.se/), after which manual samples were drawn from a 196 
radial artery cannula at 4.5, 7.5, 11,15, 20, 25, 30, 35, 40, 45, 50 and 60 minutes. 197 
Plasma metabolite samples were also manually drawn from the radial artery at 4.5, 198 
11, 15, 20, 30, 45 and 60 minutes. The amount of unchanged [18F]FMPEP-d2 and its 199 
radioactive metabolites were analysed from arterial plasma samples using thin-layer 200 
chromatography and digital autoradiography; see supplementary methods for details. 201 
 202 
2.5 Plasma input curve preprocessing 203 
 204 
Decay corrected whole blood tissue activity curves (TAC) derived from automatic 205 
blood pump sampling were converted to plasma activity using hematocrit and a 206 
population derived tracer specific distribution function. Automated and manual 207 
plasma sample TACs were then combined. Plasma TAC values were extrapolated 208 
from 60 to 120 minutes using a biexponential function fit starting at two times the 209 
peak activity location. The measured and estimated plasma activities were corrected 210 
for the fraction of unchanged tracer, which was interpolated with a Hill-function fit to 211 
the measured un-metabolized fraction time series. The time delay of the peak 212 
radioactivity reaching tissue and blood samples was corrected using PET count rate 213 
curves to reference of peak tissue activity. The resulting plasma activity concentration 214 
curve, corrected for metabolites, was used as parent input for modeling. 215 
 216 
2.6 Assessment of confounding factors in blood data 217 
 218 
To assess sources of variation in VT, statistical tests of blood data were done with sex 219 
as the independent variable. Areas under curve (AUC) for parent input and unchanged 220 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 7
tracer fraction time series were calculated with the linear trapezoidal method using 221 
GraphPad Prism version 6.00 (GraphPad Software, La Jolla California USA, 222 
www.graphpad.com). Sex differences of whole parent input AUC means were 223 
compared with Student’s t-test. Repeated measures analysis of variance (rmANOVA) 224 
within the general linear model framework (GLM) was used to test for a significant 225 
group effect or time*sex interaction in unchanged tracer fractions. Associations of 226 
blood data to body mass index (BMI) and age were explored by calculating Pearson 227 
correlation coefficients. The sources of variance in parent input were modeled with 228 
linear regression using body surface area (BSA), injected activity and AUC of 229 
unmetabolized tracer fraction as independent variables. 230 
 231 
2.7 Tissue data characterization 232 
 233 
Individual tissue time activity curves (TTAC) were visually inspected for quality. 234 
There were no significant hemispheric differences of regional VT (df=1, F=0.563, 235 
p=0.461) in an rmANOVA model including all 17 ROIs and two hemispheres as 236 
within-subject factor levels. VT from VOIs containing both hemispheres from the 237 
amygdala, anterior cingulate cortex, brainstem, cerebellum, frontal cortex, 238 
hippocampus, insula, nucleus caudatus, occipital cortex, orbitofrontal cortex, 239 
parahippocampal cortex, parietal cortex, posterior cingulate cortex, prefrontal cortex, 240 
putamen, temporal cortex and thalamus were chosen for further statistical testing. 241 
 242 
2.8 Modeling of VOI VT and subgroup comparisons 243 
 244 
In this study regional [18F]FMPEP-d2 VT was calculated using Logan plot47, a 245 
multiple time graphical analysis method, with fit start fixed at 42 minutes. Logan plot 246 
VT has been shown to produce similar regional retest variabilities (13-18%) and ICCs 247 
(.85-.93) as 2-tissue compartmental modeling (9-17% and .85-.94 correspondingly), 248 
and is highly correlated (R2=.96-.98) with 2-tissue compartmental model derived 249 
whole brain VT47. Logan plot adds minor underestimation bias due to noise and 250 
provides robust measurements of VT at both regional and voxel level48. A substantial 251 
proportion of CB1R has been found to be internalized behind the neuronal plasma 252 
membrane49. The proportion of internalized receptors might vary between brain 253 
regions. Logan plot permits not assuming a uniform model structure for the whole 254 
brain. Modeling was done with in-house developed software, which is freely available 255 
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for download online (http://www.turkupetcentre.net/software/). Shapiro-Wilks test 256 
was used to test the normality assumption. Correlations with subject age and BMI 257 
were assessed with Pearsons r correlations. Repeated measures ANOVA was used to 258 
test for differences in VT between sexes. Greenhouse-Geisser correction was used 259 
when sphericity assumption was violated. Results from rmANOVA were reassured by 260 
leaving out thalamic and caudate nucleus VOIs in which the normality assumption 261 
was violated. Group differences in these two VOIs were tested with Mann-Whitney 262 
U-test. P-values <0.05 were considered statistically significant. All statistical testing 263 
was done with IBM SPSS Statistics 23 software (IBM corp. Armonk, NY, USA). 264 
 265 
2.9 Voxel-wise modeling and statistical testing of VT 266 
 267 
Parametric images of VT were calculated to discover the maximal sources of variance 268 
within regions, and to reassure results from VOI tests. First, the skull signal was 269 
masked out to minimize the effect of Gaussian filtering activity from skeletal 270 
[18F]fluoride accumulation onto the cortical signal. The motion corrected PET images 271 
were then Gaussian filtered to the approximate spatial resolution (FWHM 3 mm) of 272 
HRRT to increase signal to noise ratio. Freely available in-house software was used to 273 
calculate voxel-wise VT  (http://www.turkupetcentre.net/software/). Modeling was 274 
started from the frame starting at 42 minutes without VT constraints. The parametric 275 
volume was then Gaussian filtered (FWHM 10 mm) and normalized to standard MNI 276 
space using transformations obtained by aligning the T1 weighted MR image to a 277 
standard MNI template using SPM12. Concordance of VOI level VT from the 278 
prefrontal cortex and putamen were tested against mean VT from corresponding areas 279 
of MNI normalized parametric volumes using Pearson r correlations. An independent 280 
sample t-test was done with SPM12 to compare groups at voxel level. The threshold 281 
of statistical significance used in the VOI level tests of sex difference (p<0.05) was 282 
used as peak threshold for corresponding parametric t-tests. In exploratory analyses, 283 
the peak threshold was set at p<0.001. In all parametric analyses the FDR corrected 284 
cluster threshold was p<0.05 and the extent threshold was adjusted to the size of the 285 
smallest significant cluster. 286 
 287 
 288 
 289 
 290 
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2.10 Neuropsychological testing 291 
 292 
All subjects participated in neuropsychological testing including Trail Making Test A 293 
(TMT-A), Brief Visuospatial Memory Test (BVMT), a visuospatial working memory 294 
task (Spatial Span), word fluency, Hopkins Verbal Learning Test (HVLT) and 295 
Continuous Performance Test (CPT-IP). Gender differences in performance were 296 
tested for each test separately using univariate GLM including age as a covariate. 297 
3 RESULTS 298 
 299 
All subjects were of Finnish ancestry. Males and females did not differ in age, years 300 
of education, level of functioning, smoking status, handedness, average movement 301 
during PET scan or injected tracer activity; table 1. Additionally, there were no 302 
differences in self-reported anxiety (Beck Anxiety Inventory). Males had a larger 303 
body surface area than females (df=20, t=4.496, p<0.001), but there was no difference 304 
in BMI (p=0.250). There were no significant correlations between age (p>0.150) or 305 
BMI (p>0.180) and VT in any VOI, with or without controlling for sex. There were no 306 
significant differences of VT between hemispheres (df=1, F=0.563, p=0.461). 307 
Therefore, VT from bilateral VOIs were used in statistical models. Results of 308 
statistical tests of blood data, and comparison of parametric and ROI VT, can be found 309 
in supplement 2. A figure showing the time series of mean un-metabolized tracer 310 
fractions in males and females separately can be found in supplement 3. 311 
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Table 1 Demographic, clinical and imaging information of study groups 
 Male Female P-value 
Number of subjects (N) 11 11  
Right-handed (N) 11 11  
Age (years) 27±6 28±10 .72 
BMI (kg m-2) 25±4 24±3 .25 
Years of education 16±3 16±3 .95 
SOFAS 91±5 93±5 .36 
Tobacco smokers/non-smokers (N) 1/10 1/10  
AUDIT score 9±6 5±3 .23 
Lifetime cannabis use >5 times (N) 3 0 .214 
Past year cannabis use <6 times (N) 3 0 .214 
Injected [18F]FMPEP-d2 activity (MBq) 200±13 205±13 .36 
Injected [18F]FMPEP-d2 mass (ng) <189 <194  
BSA (m2) 2.0±.14 1.8±.12 <.001 
Parent plasma input AUC (kBq/ml*min) 132±32 188±25 <.001 
Un-metabolized tracer fraction AUC (1*min) 1613±179 1918±417 .08 
Average frame-to-frame movement (mm) .42±.17 .45±.13 .30 
Values are number, or mean±standard deviation. Abbreviations: AUC, area under 
curve; AUDIT, alcohol use disorders identification test; BMI, body mass index; BSA, 
body surface area; SOFAS, social and occupational functioning assessment. 
 312 
3.1 Region of interest analyses of CB1R VT in males and females 313 
 314 
The VT of [18F]FMPEP-d2 was higher in males compared to females (df=1, F=13.150, 315 
p=0.002), in a regionally differential manner (VOI*sex interaction: df=2.528, 316 
F=7.114, p=0.001). The VT of males was significantly higher (p<0.05) in all studied 317 
brain regions. The largest effect sizes were found in the occipital cortex (η2=0.530, 318 
t=4.746, p<0.001), parietal cortex (η2=0.455, t=4.087, p=0.001) and the posterior 319 
cingulate cortex (η2=0.437, t=3.941, p=0.001); figure 1. Inter-subject variation was 320 
similar in male and female groups. However, females using oral contraceptives tended 321 
to have lower mean VT than females without contraception or recent menopause. Due 322 
to low number of subjects in the subgroups no further statistics were attempted; figure 323 
2. 324 
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 325 
Figure 1. VT of [18F]FMPEP-d2 is higher in males (grey bars, n=11) than in females 326 
(black bars, n=11) in a regionally differential manner. The bars, representing group 327 
means in 17 VOIs, are arranged in order of increasing maximum mean VT. Error bars 328 
indicate standard error of mean. Abbreviations: BSTEM, brainstem; THA, thalamus; 329 
CER, cerebellum; OCC, occipital cortex; HIPP, hippocampus; CAU, caudate 330 
nucleus; PHIPP, parahippocampal gyrus; PAR, parietal cortex; PCC, posterior 331 
cingulate cortex; AMY, amygdala; FC, frontal cortex; PFC, prefrontal cortex; INS, 332 
insula; OFC, orbitofrontal cortex; TEMP, temporal cortex; ACC, anterior cingulate 333 
cortex; PUT, putamen. *P<0.05; **P<0.01, repeated measures ANOVA. +P<0.05; 334 
++P<0.01, Mann-Whitney U-test. 335 
 336 
 337 
Figure 2. Scatter plots show higher [18F]FMPEP-d2 VT in males (n=11) compared to 338 
females (n=11) in the occipital cortex (left) and the prefrontal cortex (right). Female 339 
subjects using combined oral contraceptives, no contraceptives, or in menopause are 340 
denoted with either closed squares (, n=6), open squares (, n=4), or a diamond 341 
(, n=1), respectively. 342 
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3.2 Parametric image analyses 343 
 344 
A voxel-wise t-test showed one large significant cluster of higher VT in males than 345 
females (kE≥250679, pFDR-corr<0.001); figure 3. Voxel-wise regression analyses 346 
revealed two significant clusters (pFDR-corr<0.05) of parametric VT correlated 347 
negatively with visuospatial working memory task (Spatial span) performance. Sex 348 
was used as a covariate; figure 4. However, only the left hemisphere cluster survived 349 
correcting the cluster extent threshold for multiple comparisons (pFWER-corr<.008). 350 
There were no gender differences in visuospatial working memory test scores in this 351 
sample (df=20, t=-0.537, p=0.597), nor significant associations of other 352 
neuropsychological test performance with parametric CB1R VT.  353 
 354 
355 
Figure 3. Statistical parametric mapping (SPM) analysis shows one cluster of higher 356 
VT in males (n=11) compared to females (n=11). The cluster, visualized here in two 357 
horizontal planes representing high T-values, was significant after FDR correction 358 
(pFDR-corr<0.001, kE≥250679). The lower limit of the color bar denotes T-score height 359 
threshold and the upper limit denotes maximum peak value (-21mm, -54mm, 14mm). 360 
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 361 
 362 
Figure 4. SPM analysis shows two clusters where behavioural visuospatial working 363 
memory task performance was negatively correlated with VT. The clusters are shown 364 
mapped onto inflated cortical surfaces of the left and right hemispheres separately. 365 
See supplement 3 for visualization of the clusters in glass brain. The left cluster was 366 
significant after FDR correction (pFDR-corr=0.001, kE≥12011). The right cluster was 367 
significant after FDR correction (pFDR-corr=0.011, kE≥6887), but did not survive 368 
correction for multiple comparisons (pFWER-corr<.008). The lower limit of the color bar 369 
denotes T-score height threshold and the upper limit denotes maximum peak value (-370 
36mm, 18mm, 28mm). Symbols mark the cortical area of association (*: middle 371 
frontal gyrus and sulcus; **: inferior frontal sulcus and inferior part of precentral 372 
sulcus; ▲: central sulcus; ▲▲ : intraparietal sulcus and transverse parietal sulci; 373 
▲▲▲: superior frontal gyrus, and anterior cingular gyrus and sulcus; +: superior 374 
frontal sulcus; ++: circular sulcus of the insula; +++: anterior cingular gyrus and 375 
sulcus). 376 
4 DISCUSSION 377 
 378 
In this study we found a higher VT of [18F]FMPEP-d2 in males compared to females. 379 
Our results are in good agreement with previous animal studies. The binding of CB1R 380 
agonist [3H]CP55,940 is consistently higher in male rats12–14. Also, higher anterior 381 
pituitary CB1R mRNA and hippocampal CB1R protein levels have been measured in 382 
male rats using in situ hybridization and western blot experiments10,11. Sex differences 383 
in ECS responses to stress have also been reported. CB1R agonist [3H]CP55,940 384 
binding in response to prenatal and postnatal stress is different, with reduced binding 385 
in male rats and elevated binding in females14. Chronic unpredictable stress also 386 
results in reduced CB1R protein levels in male adolescent rats, while female levels 387 
increase10. Maternal deprivation stress in turn associates with reduced 388 
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immunoreactive CB1R proteins in male rats19, and subtle increases of [3H]CP55,940 389 
binding in female rats13.  390 
 391 
While preclinical results largely parallel each other, previous human PET studies on 392 
sex difference of brain CB1R are inconsistent. Lower CB1R VT was reported in males 393 
using [11C]OMAR PET15,16, while an opposite finding was reported by another study 394 
using standardized uptake values of [18F]MK-9470 PET17. The human studies on 395 
CB1R sex difference are largely comparable in terms of age, BMI and years of 396 
education of healthy control subjects. However, since the ECS interact bi-397 
directionally with sex hormones50, inconsistencies between results may be due to 398 
differences in hormonal status of female subjects. For example, circulating estradiol 399 
levels can vary ten-fold during the normal ovarian cycle44. Estrogen significantly 400 
affects CB1R agonist binding51 and increase AEA synthesis in the hypothalamus52, 401 
while AEA regulates central gonadotropin secretion influencing sex steroid levels52. 402 
Previous literature on sex difference of endocannabinoid levels in cerebrospinal fluid 403 
or peripheral blood is inconclusive with mixed results. Most studies report no major 404 
differences of EC levels between males and females53–62 but the link between 405 
peripheral ECS drive and central CB1 receptor availability is not known63. In our 406 
sample, females using combined oral contraceptives, a combination of estrogen and 407 
progesterone, tended to have lower mean CB1R availability compared to that of 408 
females without hormonal contraception. The inter-subject variation of [18F]FMPEP-409 
d2 VT within the studied areas did not differ between males and females suggesting 410 
that the putative effect of combined oral contraceptives, or estrous cycle status, is 411 
subordinate to the overall sex effect64. However, the effect of contraceptives on CB1R 412 
availability cannot be generalized due to cross-sectional study design and a small 413 
sample size. It is possible that this association is caused by other circumstances co-414 
occurring with oral contraceptive use. Notably one previous study reported that CB1R 415 
binding did not differ between premenopausal females on and off contraceptives17. 416 
The lack of detailed estrous cycle data and used contraceptive characteristics makes it 417 
very difficult to assess comparability of studies in this regard15–17. 418 
 419 
It is notable that the previous study reporting a lower CB1R availability in males used 420 
[11C]OMAR as a PET tracer, which is a rimonabant analogue CB1R antagonist. It is 421 
functionally similar to inverse agonist radioligands [18F]FMPEP-d2 and [18F]MK-422 
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9470, which in turn demonstrated higher CB1R availability in males. The latter 423 
radioligands have markedly slower kinetics, greater affinities and higher lipophilities 424 
compared to [11C]OMAR. Both [18F]FMPEP-d2 and [11C]OMAR exhibit specific 425 
binding to CB1R that can be displaced with rimonabant. However, this does not 426 
necessarily mean that the tracers label exactly same receptor populations. A 427 
substantial portion of CB1R are known to undergo receptor internalization processes 428 
49
, the CB1R exists in multiple affinity states in relation to agonist activity65, and 429 
appears to have many regulatory protein interactions66. More specifically, CB1R exist 430 
in an active conformation associated with coupling to and activating G-proteins, as 431 
well as an inactive conformation67,68. Antagonists/inverse antagonists have equal 432 
affinities to the active and inactive states of CB1R, and agonists have preference for 433 
the active state. While a substantial majority of CB1R on the neuronal membrane 434 
reside in the inactive state, agonists are thought to shift this proportion of 435 
active/inactive conformities towards the active state.65 It is thus possible that using 436 
radiotracers differing in affinity, lipophilicity, receptor-ligand interactions, and scan 437 
times may lead to differences in distribution volumes. For example, varying degrees 438 
of radioligand displacement by endogenous agonists can lead to differing populations 439 
of receptor states and cellular compartment distributions represented by VT. It is not 440 
known whether [18F]FMPEP-d2 VT is affected by endogenous agonists, but this 441 
would be unlikely considering that [11C]MePPEP, a close structural relative, is not 442 
displaced by endogenous agonists or synthetic agonists even at potent levels69. This 443 
indicates that [18F]FMPEP-d2 V  is rather an index of CB1R availability than receptor 444 
affinity meaning limited sensitivity to endogenous ligand competition at CB1Rs. To 445 
our knowledge no such data is available for [11C]OMAR. Moreover, the proportion of 446 
non-displaceable binding to displaceable binding of [18F]FMPEP-d2 has been 447 
previously reported to be small33, and any non-significant differences in the transport 448 
of tracer from blood to tissue compartments are very unlikely to explain any robust 449 
differences in VT. 450 
 451 
Opposite results of CB1R VT using [18F]FMPEP-d2 and [11C]OMAR have been 452 
reported also in studies of alcohol dependence in males. [18F]FMPEP-d2 VT remained 453 
lower compared to controls after 2-4 weeks of abstinence39, while [11C]OMAR VT 454 
was higher after 4 weeks of alcohol abstinence70. Additionally, in a study of CB1R in 455 
cannabis dependence, cannabis dependent males had ~20% lower [18F]FMPEP-d2 VT, 456 
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which increased to control levels after 4 weeks of abstinence38. Chronic cannabis use 457 
similarly resulted in ~15% lower VT with [11C]OMAR. However, this level increased 458 
significantly after only two days of abstinence71. The initial depression is consistent 459 
with CB1R down-regulation secondary to chronic CB1R agonist ∆9-THC exposure72–460 
74
, but the prompt increase of VT could also be explained by depletion of cumulated 461 
∆9-THC from adipocytes75. 462 
 463 
Curiously, higher binding of [3H]OMAR to prefrontal cortex cryo-sections was found 464 
to be inversely associated to CB1R protein and mRNA levels in an ex vivo sample of 465 
schizophrenia patients76. This was suggested to reflect alterations in receptor affinity, 466 
or trafficking within the neuron. Differences in tracer selectivity balances of 467 
CB1R/CB2R binding, inverse association of [11C]OMAR to CB1R agonist activity, or 468 
related affinity changes, could also explain the results discussed above. However, 469 
these suggestions are highly speculative and cannot be resolved without a cross 470 
validation study with [11C]OMAR and [18F]FMPEP-d2, or characterization of 471 
radioligand displacement in vivo by different cannabinoids. 472 
 473 
Definitive conclusions about the functional consequences of the observed sex 474 
difference cannot be made at this time due to the elusive and highly intricate 475 
regulation of CB1R protein expression, trafficking and degradation. One possible 476 
explanation is that higher CB1R availability in males could reflect regulation of 477 
receptor protein density in the context of lower ECS signaling. This interpretation is 478 
supported by previous observations of reduced CB1R VT secondary to chronic 479 
cannabis use38, and reduced CB1R mRNA74 and agonist binding72 after chronic ∆9-480 
THC in adult male rats. Genetic and pharmacological knockout of monoacylglycerol 481 
lipase (MAGL), the main degradative enzyme of 2-AG, induces CB1R 482 
downregulation and desensitization in the mouse brain77, which suggests that the sex 483 
difference in CB1R availability may be mediated by 2-AG signaling. However, the 484 
regulation of CB1R mRNA and protein is complex, as shown in a cell culture study of 485 
acute and chronic endocannabinoid effects73. Here AEA and 2-AG seemed to display 486 
functional selectivity for second messenger activation, which has relevance for rates 487 
of receptor internalization, subsequent degradation, and replenishment of presynaptic 488 
membrane CB1R populations. Since endocannabinoid synthesis pathways are 489 
dissociated and differentially regulated5,78,79, it is also possible that the current 490 
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findings may be explained by alterations in endogenous cannabinoid agonists such as  491 
specific balances of AEA and 2-AG levels. Allosteric CB1R modulators 492 
pregnenolone and lipoxin A4 might also contribute to the observed effect80.  493 
 494 
The CB1R sex difference was regionally specific with statistically significant 495 
differences in both cortical and subcortical regions. The largest effect of different 496 
CB1R availability in males and females was centered in and around the posterior 497 
cingulate area, which contains the retrospenial cortex (RSC) and parahippocampal 498 
cortex (PHC). These areas are suggested to encode the spatial layout and location of 499 
specific visual scenes within a larger spatial environment81. Recently, sex differences 500 
in functional association of these areas to scene-selective stimuli were replicated in a 501 
large sample of healthy controls82. The RSC has been also suggested to be responsible 502 
for transformation of information from a self-centered viewpoint to a world-centered 503 
spatial framework83, and has also been found to be involved in speech production and 504 
comprehension84. Although the nature of RSC processing of speech is not known, it is 505 
intriguing to speculate the implications of putative dysfunctional spatial encoding of 506 
internal speech in the context of auditory hallucinations. Functional connectivity of 507 
the RSC to the superior temporal gyrus, an area involved in auditory processing and 508 
language comprehension, seems to be increased in schizophrenia85. It is thus possible 509 
that a lower ECS drive in males could result in a predisposition to aberrant spatial 510 
encoding of speech, manifesting as a vulnerability to auditory hallucinations. 511 
 512 
We also found negative associations of visuospatial working memory performance to 513 
CB1R availability. The associated areas correspond to cortical regions previously 514 
suggested to participate in visuospatial working memory, and processing of the 515 
attentional priority of memory content86,87. We suggest that ECS tonus modulates the 516 
balance of excitation and inhibition of cortical primary neurons in a bilateral occipito-517 
parieto-frontal network responsible for sustaining behaviorally relevant visuospatial 518 
content in working memory. For example, lower ECS tone could reduce 519 
synchronisation of excitatory afferents and cortical activity, via reduced suppression 520 
of inhibition in cortical interneurons, resulting in gradual drifting of working memory 521 
content from the origin88. The observed association parallels the effects of exogenic 522 
CB1R agonists on spatial working memory performance25,30. It is possible that, by 523 
disrupting the temporal-spatial selectivity of endocannabinoid neurotransmission, 524 
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exogenous agonists similarly impair synchronised neural oscillations. On the other 525 
hand, an overactive ECS could also result in ineffective working memory through 526 
excessive high-pass filtering of pertubing excitatory activity. 527 
 528 
It is notable that males and females did not differ in years of received education, level 529 
of functioning, or neuropsychological test scores. Thus, the observed association to 530 
visuospatial performance could be secondary to a compensated developmental factor. 531 
This indicates that the ECS is calibrated during neurodevelopment to provide an 532 
optimal behavioral level in the context of other neurotransmitter system states89, 533 
hormonal influences90 and/or environmental influences19. However, this interpretation 534 
is restricted by insufficient statistical power. Subtle sex differences in visuospatial test 535 
performance in our sample cannot be entirely ruled out. The ECS may also be 536 
involved in other neuropsychological functions with putative sex differences, such as 537 
verbal fluency91. 538 
 539 
The ECS affects biologically fundamental brain functions by gating the 540 
hypothalamus-pituitary-adrenocortical axis (HPAA) stress response92, and striatal 541 
dopamine release by local circuit modulation of amygdala and midbrain efferents 542 
respectively93. Differences of ECS drive in males and females might thus manifest as 543 
different sensitivies to HPAA activity, or striatal dopamine release in response to 544 
stress94, a transdiagnostic psychiatric risk factor95. This theoretical link between sex 545 
dependent psychiatric vulnerabilities and the ECS is supported by observations of the 546 
intermediary role of the ECS in estradiol effects on addiction90 and anxiety 547 
behaviour96 in female rats. Estradiol also seems to affect hippocampal inhibitory 548 
interneuron activity differently in male and females through an ECS dependent 549 
mechanism97. Whatever the origin, alternate tones of CB1R mediated modulation 550 
could nevertheless be manifested as differences in cognitive performance and 551 
responses to stress. Studying ECS function separately in male and female psychosis 552 
patients or other relevant syndromes are needed to elucidate whether the observed sex 553 
differences are relevant in the context of psychiatric vulnerability.  554 
 555 
 556 
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5 CONCLUSIONS 557 
 558 
We observed robust gender differences in CB1R availability with large effect sizes. 559 
The widespread effect was regionally selective with the most pronounced effects 560 
observed in the posterior limbic cortex. Our results also suggest an association 561 
between CB1R availability and visuospatial functioning, a domain suggested to have 562 
sex differences in the general population. In addition, combined hormonal 563 
contraceptives seemed to affect CB1 receptor availability but this should be further 564 
investigated with a larger sample size and detailed characterization of hormonal 565 
status. Finally, these results implicate that future human studies of ECS function in 566 
different neuropsychiatric disorders should closely control the effects of sex and 567 
hormonal status. 568 
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